BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview

2024/08/15 22:0	0:01	
Price 5.74 USD		
Difference	0	3.80% (0.21)

General attributes				
CA0717341071				
ВНС				
NYSE				
USD				
Other				
Stock				
1,920 EUR				
S&P/TSX 60 INDEX				

Market data	
Bid (Bid size)	2.30 USD (200)
Ask (Ask size)	6.40 USD (100)
Open	5.65 USD
High	5.88 USD
Low	5.62 USD
Close (prev. day)	5.53 USD
VWAP	5.769428 USD
Volume (pcs)	1,242,195
Trading volume	7,167,688.29
Number of trades	9,912
Last size	-

Futures and Options	
Related Futures	15
Related Options	-

PDF Downloads	
Company report: BAUSCH HEALTH COMPANIES INC.	.₽.



Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

on sector			
Date		Headline	Download
2024/08/12	60. 126 621 126	Global Equity Ratings	
2024/07/24	85. L26 27. 178	Global Equity Ratings	
2024/07/12	80 Jan 80 TS	Global Equity Ratings	
2024/06/21	55. Let 27. 1%	Global Equity Ratings	
2024/06/14	80 Jan 80 TS	Global Equity Ratings	




Details

2024/08/15 22:00:01				
Price				
5.74 USD				
Difference	0	3.80% (0.21)		

General attributes			
ISIN	CA0717341071		
Symbol	ВНС		
Exchange	NYSE		
Currency	USD		
Sector	Other		
Security type	Stock		
Market cap (m)	1,920 EUR		
Benchmark	S&P/TSX 60 INDEX		

Market data	
Bid (Bid size)	2.30 USD (200)
Ask (Ask size)	6.40 USD (100)
Open	5.65 USD
High	5.88 USD
Low	5.62 USD
Close (prev. day)	5.53 USD
VWAP	5.769428 USD
Volume (pcs)	1,242,195
Trading volume	7,167,688.29
Number of trades	9,912
Last size	-

Performance and Risk					
	6m	1Y	3Y		
Perf (%)	-33.62%	-31.34%	-77.59%		
Perf (abs.)	-2.65	-2.39	-18.13		
Beta	1.89	1.60	1.81		
Volatility	57.49	49.04	73.05		



Information about previous performance does not guarantee future performance. $\textbf{Source:} \ \ \textbf{FactSet}$

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	5.52 USD (1,093,820)
Ø price 30 days Ø volume 30 days (pcs.)	6.43 USD (5,169,502)
Ø price 100 days Ø volume 100 days (pcs.)	7.31 USD (3,724,310)
Ø price 250 days Ø volume 250 days (pcs.)	7.73 USD (2,976,066)
YTD High date	11.46 USD (2024/04/03)
YTD Low date	3.96 USD (2024/07/24)
52 Weeks High date	11.46 USD (2024/04/03)
52 Weeks Low date	3.96 USD (2024/07/24)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/08/ 16	11:44	5.308 EUR	0.00	3
Toronto Stock Exchange	2024/08/ 15	22:00	7.88 CAD	2.55	1,450
Stuttgart	2024/08/ 16	11:05	5.208 EUR	0.00	2
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/08/	22:00	5.74 USD	7.17	9,912



	15				
Munich	2024/08/ 16	08:08	5.158 EUR	0.00	1
Frankfurt	2024/08/ 16	08:08	5.156 EUR	0.00	1
Duesseldorf	2024/08/ 16	08:10	5.152 EUR	0.00	1
Berlin	2024/08/ 16	80:80	5.158 EUR	0.00	1



Company profile

Company Logo

BAUSCH Health

Contact Details

BAUSCH HEALTH COS. INC.

_ _

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Mellipers of M	Wellibers of Management Board			
Thomas Appio	Chairman of Managing Board			
Tage Ramakrishna	Member of Executive Committee			
Cees Heiman	Member of Executive Committee			
Fernando Zarate	Member of Executive Committee			
Graham Jackson	Member of Executive Committee			
Jeff Hartness	Member of Executive Committee			
Kathleen Fitzpatrick	Member of Executive Committee			
Mirza Dautbegovic	Member of Executive Committee			

Member of Executive

Member of Executive

Committee

Committee

Seana Carson

Tom Vadaketh

Members of Management Roard

æ,

Board of directors		
John Paulson	Chairman of Supervisory Board	
Amy Wechsler	Member of Supervisory Board	
Richard Mulligan	Member of Supervisory Board	
Brett Icahn	Member of Supervisory Board	
Christian Garcia	Member of Supervisory Board	
Frank Lee	Member of Supervisory Board	
Robert Power	Member of Supervisory Board	
Sarah Kavanagh	Member of Supervisory Board	
Steven Miller	Member of Supervisory Board	

